LENSAR Becomes Subsidiary of PDL, Gains FDA Clearance for Laser Integration with Pentacam, Aladdin

May 12, 2017: By Joan McKenna

LensarLENSAR, Inc., announced May 11 that it has completed its financial restructuring, with a court-approved exit plan from bankruptcy. As part of the plan, PDL BioPharma will convert most of its debt to an equity ownership position. LENSAR will become a wholly owned subsidiary of PDL, and PDL will begin to consolidate LENSAR’s financial statements.

LENSAR is one of five companies marketing femtosecond lasers for cataract surgery. The Orlando, Florida, company declared bankruptcy in December 2016 in a strategic restructuring designed to separate the business from Alphaeon—Alphaeon acquired LENSAR in late 2015 for a reported $59 million.

On May 5, LENSAR announced it had gained US FDA 510(k) clearance for integration of the Oculus Pentacam and Topcon Aladdin topographers with the LENSAR Laser System with Streamline III.

The LENSAR laser already provided direct integration with the Cassini Corneal Shape Analyzer and the Nidek ODP.

LENSAR describes its next-generation system as designed to help surgeons “manage astigmatism with extreme treatment planning insights.” The company said its incorporation of the diagnostic technology expands the potential customer base.

“Our open architecture platform allows surgeons to use the diagnostic devices they trust to guide treatment and manage astigmatism using our laser’s exclusive features to ultimately deliver the outcomes and experience today’s patients demand from an advanced cataract procedure,” said Nicholas Curtis, CEO of LENSAR.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

US Health Secretary Alex Azar Takes Aim at Rebates in US Senate Hearing

Beyeonics Surgical Raises $11.5 Million in Initial Funding Round

MeiraGTx Raises $75 Million in Initial Public Offering

GenSight to Pursue Approval for LHON Gene Therapy Candidate, Despite Phase III Setback

Optovue Receives FDA Clearance for AngioAnalytics, First OCT Angiography Metrics

Nexy Robotic Retinal Imaging System Receives FDA Clearance

Ocutrx Receives US Patent for Oculenz AR Glasses for Macular Degeneration

Allergan’s Bimatoprost SR Demonstrates Noninferiority to Timolol in Phase III Glaucoma Study

KKR to acquire Envision Healthcare, Including Amsurg ASC Business

Ophthalmologist Carmen Puliafito, MD, Seeks to Regain Medical License

Avedro Gains J Code for Photrexa Formulations in Preliminary CMS Decision

EyeGate Seeks to Study Ocular Bandage Gel in Punctate Epitheliopathy

Nicox, Ironwood to Collaborate on Novel Ophthalmic Treatments

US FDA Approves MDGH’s Moxidectin for Treatment of River Blindness

Bausch + Lomb Enrolls First Patient in Trial for enVista MX60EF Trifocal IOL

Cincinnati Eye Institute Partners with Private Equity Firm to Pursue National Expansion

Ophthotech Enters Gene Therapy Deals with University of Florida, University of Pennsylvania

Teva’s Launches Generic Version of Restasis in Canada

Clearside’s Phase II Trial for DME Candidate Meets Primary Endpoint

Orasis Raises $13 Million in Series B Financing

Coming soon

2018 Optical Coherence Tomography Report: A Global Market Analysis for 2017 to 2023